Techniques自噬信号通路-Autophagy Singaling Pathway
自噬信号通路-Autophagy Singaling Pathway
——研究自噬从选择好的化合物开始
自噬按照吞噬物进入溶酶体的途径,可分为分子伴侣介导的自噬(chaperone-mediated autophagy),微自噬(microautophagy)和巨自噬(macroautophagy),通常所说的自噬(autophagy)指的是巨自噬。自噬最终是通过自噬泡与溶酶体的融合,来完成对大量胞质内容物,异常蛋白质以及过剩或受损细胞器的降解。通常自噬发生在营养缺乏的情况下,但也可能与生理和病理过程有关,例如发育,分化,神经退行性疾病,应激,感染和癌症。
自噬5大关键过程:
(1)自噬泡(phagophore)的形成:
(2)Atg5-Atg12-Atg16L复合物形成并与自噬泡融合;
(3)微管相关蛋白轻链3(microtubule-associatedprotein light chain3,LC3)由可溶解形式(LC3-I)转变为脂溶形式(LC3-II),与自噬泡结合形成自噬体。
(4)自噬体捕获需降解或清除的蛋白质、细胞器等物质;
(5)自噬体与溶酶体结合形成自噬溶酶体(autolysosomes),在自噬溶酶体内自噬体内层膜,内容物在溶酶体内降解。过程详见图1。
| |||
起始 | 延伸 | 融合 | 降解 |
Initiation | Expansion | Fusion | Degradation |
图1:自噬发生图解。UKL和Beclin 1蛋白复合物起始自噬泡的形成,Atg5/12/16与LC3-II负责自噬体的延伸,最后自噬体与溶酶体融合,释放内容物,完成自噬。 | |||
自噬相关化合物:
自噬诱导剂(inducer) | |||
产品名称 | 货号 | 规格 | 靶点 |
51207ES03 | 1g | AMPK activator | |
52409ES08 | 5mg | Akt inhibitor | |
52404ES10 | 10mg | mTOR inhibitor - TLR signaling inhibitor | |
52411ES25 | 25mg | mTOR inhibitor | |
52801ES08 | 5mg | 26S proteasome inhibitor | |
51408ES70 | 200mg | Pan-Histone deacetylase Inhibitor | |
51502ES03 | 5mg | Reprogramming Enhancer -Histone deacetylase Inhibitor | |
40328ES25 | 25μl | General Caspase Inhibitor | |
自噬抑制剂(inhibitor) | |||
产品名称 | 货号 | 规格 | 靶点 |
52003ES10 | 10mg | MAP Kinase Inhibitor - JNK inhibitor | |
52004ES08 | 5mg | MAPK Kinase ,MEK1,MEK2 Inhibitor | |
52403ES08 | 5mg | PI3K inhibitor | |
52405ES03 | 1mg/ml | PI3K inhibitor | |
51301ES08 | 5mg | Abl,Abl(E255K)和Abl(T315I) | |
更多产品敬请详询400-6111-883
Not listed yet IMG Brefeldin A (BFA, 5 mg/mL) 布雷非德菌素A(5 mg...
Not listed yet IMG Schizandrin B五味子乙素
Not listed yet IMG AS1842856
Not listed yet IMG Deferoxamine mesylate
Not listed yet IMG Chloroquine diphosphate
Not listed yet IMG Cearoin
Not listed yet IMG STF-62247
Not listed yet IMG LRRK2-IN-1
Not listed yet IMG GSK2578215A
Not listed yet IMG Brefeldin A
Not listed yet IMG Chloroquine
Not listed yet IMG PFK15
Not listed yet IMG Spautin-1
Not listed yet IMG Yangonin
Not listed yet
